| Recruiting | Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma NCT06510309 | Gottfried von Keudell, MD PhD | Phase 2 |
| Recruiting | Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL NCT07441993 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Not Yet Recruiting | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/ NCT07225439 | Paolo Caimi, MD | Phase 1 |
| Recruiting | Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma NCT07233720 | Henan Cancer Hospital | — |
| Recruiting | Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) NCT06796998 | Izidore Lossos, MD | Phase 2 |
| Recruiting | Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas NCT06300528 | University of Utah | Phase 2 |
| Recruiting | HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL NCT06792825 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas NCT07029217 | Memorial Sloan Kettering Cancer Center | Phase 3 |
| Recruiting | Combating Cancer-Related Fatigue: A Personalized Supportive Care Program NCT06860880 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Recruiting | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579 | Vironexis Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | 64Cu-LLP2A for Imaging Hematologic Malignancies NCT06636175 | Washington University School of Medicine | EARLY_Phase 1 |
| Recruiting | Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) NCT06390956 | University of Utah | Phase 2 |
| Recruiting | LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies NCT05990465 | Medical College of Wisconsin | Phase 1 |
| Recruiting | Epco, Zanu, Ritux for R/R FL or MZL NCT06563596 | Reid Merryman, MD | Phase 2 |
| Recruiting | SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265 | Verismo Therapeutics | Phase 1 |
| Enrolling By Invitation | CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas NCT07168486 | University of Maryland, Baltimore | Phase 1 |
| Recruiting | Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma NCT06566807 | Huai'an First People's Hospital | Phase 2 |
| Recruiting | Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE) NCT06534463 | Ruijin Hospital | — |
| Recruiting | Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas NCT06513234 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL) NCT06504940 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Recruiting | Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymph NCT06478472 | The First Affiliated Hospital of Xiamen University | N/A |
| Recruiting | Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Z NCT06454968 | Peking Union Medical College Hospital | Phase 2 |
| Recruiting | A Cohort Study in Newly Diagnosed MZL NCT06449885 | Fudan University | — |
| Terminated | [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma NCT06125028 | Pentixapharm AG | Phase 3 |
| Unknown | Preliminary Assessment of [18F]BL40 in PET/CT Scans NCT06224309 | British Columbia Cancer Agency | — |
| Recruiting | Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas NCT06350318 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas NCT06340737 | Stanford University | Phase 1 |
| Recruiting | Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Mali NCT06151730 | Mayo Clinic | — |
| Active Not Recruiting | BCL6-rearrangements Implications in Non-Hodgkin Lymphomas. NCT06424379 | Hospices Civils de Lyon | — |
| Recruiting | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma NCT06026319 | Marcela V. Maus, M.D.,Ph.D. | Phase 1 |
| Not Yet Recruiting | (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) NCT05923502 | Ruijin Hospital | — |
| Completed | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R NCT05665530 | Prelude Therapeutics | Phase 1 |
| Recruiting | Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone L NCT06006117 | The Lymphoma Academic Research Organisation | Phase 3 |
| Recruiting | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma NCT05602363 | Carna Biosciences, Inc. | Phase 1 |
| Active Not Recruiting | Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma NCT05783596 | Reid Merryman, MD | Phase 2 |
| Unknown | A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types NCT05907447 | Ruijin Hospital | — |
| Recruiting | Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies NCT05643742 | CRISPR Therapeutics AG | Phase 1 / Phase 2 |
| Recruiting | ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies NCT05653271 | Acepodia Biotech, Inc. | Phase 1 |
| Withdrawn | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma NCT05934097 | Fate Therapeutics | Phase 1 |
| Recruiting | Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma NCT05846750 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma NCT04792502 | Brown University | Phase 2 |
| Recruiting | Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma NCT05296070 | University of Miami | Phase 2 |
| Recruiting | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted P NCT05294731 | BeiGene | Phase 1 / Phase 2 |
| Recruiting | Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lym NCT05326308 | iOMEDICO AG | — |
| Recruiting | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukem NCT05281809 | John Lister | Phase 2 |
| Completed | Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-C NCT05169658 | University of Washington | Phase 2 |
| Terminated | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies NCT05107856 | Prelude Therapeutics | Phase 1 |
| Recruiting | A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refrac NCT05100862 | BeiGene | Phase 3 |
| Terminated | Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY NCT04268277 | University of Ulm | Phase 2 |
| Active Not Recruiting | Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells NCT04911478 | Adicet Therapeutics | — |
| Completed | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies NCT04599634 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies NCT05003141 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | Phase 1 |
| Active Not Recruiting | Study of Acalabrutinib and Tafasitamab in MZL Patients NCT04646395 | International Extranodal Lymphoma Study Group (IELSG) | Phase 2 |
| Recruiting | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies NCT05006716 | BeOne Medicines | Phase 1 / Phase 2 |
| Recruiting | Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent NCT04883437 | Emory University | Phase 2 |
| Terminated | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) NCT04745832 | MEI Pharma, Inc. | Phase 3 |
| Recruiting | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgki NCT04491370 | New York Medical College | Phase 1 / Phase 2 |
| Recruiting | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. NCT04775745 | Newave Pharmaceutical Inc | Phase 1 |
| Recruiting | A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgki NCT04669171 | Enterome | Phase 1 / Phase 2 |
| Unknown | B-cell Chronic Lymphoid Malignancies Markers NCT04952974 | University Hospital, Strasbourg, France | — |
| Active Not Recruiting | A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma NCT04416451 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocy NCT04806035 | TG Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Place NCT04680052 | Incyte Corporation | Phase 3 |
| Completed | Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma NCT04849351 | Hutchison Medipharma Limited | Phase 2 |
| Completed | Immune Responses to COVID-19 Vaccination in Lymphoma Patients NCT04858568 | University Hospital Southampton NHS Foundation Trust | — |
| Terminated | A Phase 1 Study of ADI-001 in B Cell Malignancies NCT04735471 | Adicet Therapeutics | Phase 1 |
| Active Not Recruiting | FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role NCT04333524 | International Extranodal Lymphoma Study Group (IELSG) | — |
| Completed | Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone NCT04508647 | University of Colorado, Denver | Phase 2 |
| Withdrawn | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 201 NCT04665115 | Academic and Community Cancer Research United | Phase 2 |
| Active Not Recruiting | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies NCT04072458 | Bio-Path Holdings, Inc. | Phase 1 |
| Terminated | Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma NCT04189952 | University of Miami | Phase 2 |
| Active Not Recruiting | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell NCT04542824 | Genmab | Phase 1 / Phase 2 |
| Active Not Recruiting | 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers NCT04464200 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies NCT04279405 | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 |
| Recruiting | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies NCT04186520 | Medical College of Wisconsin | Phase 1 / Phase 2 |
| Completed | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab NCT04282018 | BeiGene | Phase 1 / Phase 2 |
| Completed | VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma NCT04433156 | Henan Cancer Hospital | Phase 2 |
| Completed | BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) NCT04018248 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Terminated | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas NCT04358458 | Genmab | Phase 1 / Phase 2 |
| Withdrawn | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies NCT04043845 | Dana-Farber Cancer Institute | Phase 1 |
| Active Not Recruiting | A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma NCT04212013 | Memorial Sloan Kettering Cancer Center | Phase 3 |
| Active Not Recruiting | Copanlisib and Rituximab in Marginal Zone Lymphoma Patients NCT03474744 | Christian Buske | Phase 2 |
| Completed | Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyr NCT04116437 | BeiGene | Phase 2 |
| Terminated | A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma NCT04082936 | IGM Biosciences, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas NCT03697512 | International Extranodal Lymphoma Study Group (IELSG) | Phase 2 |
| Terminated | Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma NCT03919175 | Massachusetts General Hospital | Phase 2 |
| Terminated | Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or Mor NCT03768505 | MEI Pharma, Inc. | Phase 2 |
| Completed | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL NCT03740529 | Loxo Oncology, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001 NCT03833180 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Active Not Recruiting | Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgki NCT03884998 | City of Hope Medical Center | Phase 1 |
| Completed | Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma NCT03846427 | BeiGene | Phase 2 |
| Active Not Recruiting | Obinutuzumab in Marginal Zone Lymphoma NCT03322865 | Christian Buske | Phase 2 |
| Terminated | Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases NCT03498612 | University of Washington | Phase 2 |
| Completed | Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Ta NCT03010982 | Epizyme, Inc. | Phase 1 |
| Completed | TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade NCT03410901 | Ronald Levy | Phase 1 |
| Completed | Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas NCT03276468 | The Lymphoma Academic Research Organisation | Phase 2 |
| Completed | BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymph NCT03520920 | BeiGene | Phase 2 |
| Completed | A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies NCT03088878 | Oncternal Therapeutics, Inc | Phase 1 / Phase 2 |
| Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry NCT03452774 | Massive Bio, Inc. | — |
| Terminated | Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymph NCT03269552 | University of Washington | Phase 2 |
| Completed | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies NCT03329950 | Celldex Therapeutics | Phase 1 |
| Completed | Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin NCT03364231 | TG Therapeutics, Inc. | Phase 2 |
| Completed | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation NCT03133221 | University of Maryland, Baltimore | Phase 2 |
| Completed | A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma NCT03078855 | Jonathan Friedberg | Phase 3 |
| Active Not Recruiting | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom NCT02952508 | Cellectar Biosciences, Inc. | Phase 2 |
| Completed | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocy NCT03010358 | Alexey Danilov, MD | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 5 NCT03162536 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 / Phase 2 |
| Completed | A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma NCT03105336 | Kite, A Gilead Company | Phase 2 |
| Completed | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in P NCT03128359 | City of Hope Medical Center | Phase 2 |
| Terminated | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers NCT03037645 | Sunesis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK o NCT03028103 | Epizyme, Inc. | Phase 1 |
| Completed | Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine NCT02996773 | University of Arizona | Phase 1 |
| Completed | TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1 NCT02927964 | Robert Lowsky | Phase 1 / Phase 2 |
| Terminated | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Pa NCT02877082 | Emory University | Phase 2 |
| Terminated | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisi NCT02793583 | TG Therapeutics, Inc. | Phase 2 / Phase 3 |
| Active Not Recruiting | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma NCT02339922 | University of Washington | Phase 2 |
| Withdrawn | Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Ly NCT02623920 | University of Arizona | Phase 2 |
| Withdrawn | A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab a NCT02576275 | SecuraBio | Phase 3 |
| Terminated | Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Foll NCT02258555 | Gilead Sciences | Phase 1 |
| Completed | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relap NCT02242045 | Gilead Sciences | Phase 1 |
| Completed | Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma NCT01980628 | Pharmacyclics LLC. | Phase 2 |
| Terminated | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL NCT01728207 | Gilead Sciences | Phase 1 |
| Terminated | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies NCT01744912 | TG Therapeutics, Inc. | Phase 1 |
| Terminated | A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) NCT01500538 | Peter MacCallum Cancer Centre, Australia | Phase 2 |
| Completed | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lym NCT01647971 | TG Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies NCT01474681 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Imexon for Relapsed Follicular and Aggressive Lymphomas NCT01314014 | University of Rochester | Phase 2 |
| Completed | Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas NCT01282424 | Gilead Sciences | Phase 2 |
| Completed | Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymph NCT01306643 | Gilead Sciences | Phase 1 / Phase 2 |
| Completed | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia NCT01484015 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma NCT01239394 | Massachusetts General Hospital | Phase 2 |
| Completed | Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell NCT01239875 | Mayo Clinic | EARLY_Phase 1 |
| Withdrawn | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma NCT01460602 | Louisiana State University Health Sciences Center Shreveport | Phase 1 / Phase 2 |
| Terminated | Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma NCT01121757 | Duke University | Phase 2 |
| Terminated | Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL NCT00772668 | University of Miami | N/A |
| Completed | Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell T NCT00880815 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Lenalidomide and R-CHOP in B-cell Lymphoma NCT00901615 | Lymphoma Study Association | Phase 1 / Phase 2 |
| Completed | Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma NCT00644189 | Massachusetts General Hospital | Phase 1 / Phase 2 |
| Completed | First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. NCT00801281 | Polish Lymphoma Research Group | Phase 3 |
| Terminated | Gemcitabine for Marginal Zone Lymphoma NCT00337259 | Asan Medical Center | Phase 2 |
| Completed | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone L NCT00453102 | University of Miami | Phase 2 |
| Completed | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patient NCT00719888 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma NCT01000753 | Children's Oncology Group | — |